
|Videos|August 26, 2021
5-Year Follow-Up Data For CPX-351 in AML
Alexandra S. Wolff, PharmD, BCOP, explores the 5-year follow-up data from the phase 3 trial of CPX-351 in AML.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Earlier Menopause, Reduced Cardiac Function Potentially Linked With Negative Impacts on Brain Health
2
Menopause Care Varies by Provider, Highlighting Need for Standardized Education
3
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms
4
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
5














































































































































































































